UNCY

Unicycive Therapeutics Inc

UNCY, USA

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.

https://unicycive.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
UNCY
stock
UNCY

Unicycive stock price target lowered to $63 by Lucid Capital Markets Investing.com Nigeria

Read more →
UNCY
stock
UNCY

Vivo Capital LLC Has $5.42 Million Stock Position in Unicycive Therapeutics, Inc. $UNCY MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$46.5238

Analyst Picks

Strong Buy

4

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-16.04 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.88 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.35

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 32.86% of the total shares of Unicycive Therapeutics Inc

1.

Vivo Capital, LLC

(6.4377%)

since

2025/06/30

2.

Octagon Capital Advisors LP

(5.662%)

since

2025/06/30

3.

Nantahala Capital Management, LLC

(5.3177%)

since

2025/06/30

4.

Great Point Partners LLC

(4.5101%)

since

2025/06/30

5.

Vanguard Group Inc

(3.4309%)

since

2025/06/30

6.

Logos Global Management LP

(2.6813%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(2.6582%)

since

2025/07/31

8.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4624%)

since

2025/07/31

9.

Longwood Capital Partners LLC

(0.3561%)

since

2025/06/30

10.

Geode Capital Management, LLC

(0.3328%)

since

2025/06/30

11.

Fidelity Extended Market Index

(0.2008%)

since

2025/07/31

12.

JPMorgan Chase & Co

(0.1229%)

since

2025/06/30

13.

State Street Corp

(0.0709%)

since

2025/06/30

14.

Renaissance Technologies Corp

(0.0668%)

since

2025/06/30

15.

Lazard Asset Management LLC

(0.0655%)

since

2025/06/30

16.

Fidelity Total Market Index

(0.0616%)

since

2025/07/31

17.

Northern Trust Corp

(0.0611%)

since

2025/06/30

18.

Fidelity Series Total Market Index

(0.054%)

since

2025/07/31

19.

Goldman Sachs Group Inc

(0.0416%)

since

2025/03/31

20.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0415%)

since

2025/07/31

21.

Spartan Extended Market Index Pool F

(0.0365%)

since

2025/07/31

22.

Northern Trust Extended Eq Market Idx

(0.032%)

since

2025/06/30

23.

NT Ext Equity Mkt Idx Fd - L

(0.032%)

since

2025/06/30

24.

NT Ext Equity Mkt Idx Fd - NL

(0.0281%)

since

2025/06/30

25.

Fidelity Nasdaq Composite Index

(0.024%)

since

2025/07/31

26.

Spartan Total Market Index Pool G

(0.0233%)

since

2025/07/31

27.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0218%)

since

2025/06/30

28.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.009%)

since

2025/06/30

29.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0076%)

since

2024/12/31

30.

Morgan Stanley - Brokerage Accounts

(0.0057%)

since

2025/06/30

31.

SBI Securities Co Ltd

(0.0031%)

since

2025/06/30

32.

State St US Extended Mkt Indx NL Cl C

(0.0012%)

since

2025/08/31

33.

Northern Trust Wilshire 5000

(0.0009%)

since

2025/06/30

34.

HARBOUR INVESTMENTS, INC.

(0.0006%)

since

2025/06/30

35.

Barclays PLC

(0.0005%)

since

2025/06/30

36.

SSgA U.S. Total Market Index Strategy

(0.0005%)

since

2025/03/31

37.

Bank of America Corp

(0.0004%)

since

2025/06/30

38.

Bogart Wealth, LLC

(0%)

since

2025/06/30

39.

1290 VT Micro Cap K

(0%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.33

EPS Estimate

-0.0662

EPS Difference

-0.2638

Surprise Percent

-398.4894%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.